Oncology · Clinical trials
Neuroblastoma Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About neuroblastoma — and why its trials are hard
Neuroblastoma is the most common extracranial solid tumor of childhood, arising from developing sympathetic nervous system cells and most often diagnosed in infants and young children. Outcomes vary enormously by risk group: low- and intermediate-risk disease can be cured with surgery and limited chemotherapy or observation, while high-risk neuroblastoma—often marked by MYCN amplification—has historically had poor survival despite intensive multimodal therapy. Standard high-risk treatment combines induction chemotherapy, surgery, high-dose chemotherapy with autologous stem-cell rescue, radiotherapy, and post-consolidation therapy. A major advance was anti-GD2 immunotherapy: dinutuximab, approved in 2015 based on Children's Oncology Group study ANBL0032, significantly improved event-free and overall survival when added to isotretinoin and cytokines. Naxitamab, another anti-GD2 antibody, received accelerated approval in 2020 for relapsed/refractory bone or bone marrow disease. Isotretinoin (13-cis-retinoic acid) is standard maintenance. Despite these gains, relapsed high-risk neuroblastoma remains largely incurable, and few targeted drugs exist, underscoring a profound unmet need in pediatric oncology.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| dinutuximab (anti-GD2 antibody ch14.18) (Unituxin) | 2015 | High-risk neuroblastoma with at least partial response to prior therapy, combined with GM-CSF, IL-2, and isotretinoin | ANBL0032 (Children's Oncology Group phase III) | Event-free survival (EFS) | Improved 2-year EFS (approximately 66% vs 46%) and overall survival versus isotretinoin alone; first therapy specifically approved for high-risk neuroblastoma |
| naxitamab (anti-GD2 antibody) (Danyelza) | 2020 | Relapsed/refractory high-risk neuroblastoma in bone or bone marrow, with GM-CSF (accelerated approval, pediatric and adult) | Study 201 / Study 12-230 | Objective response rate (ORR) and duration of response | ORR approximately 45%, with durable responses in a relapsed/refractory population lacking standard options |
| isotretinoin (13-cis-retinoic acid) (generic) | 1999 | Post-consolidation maintenance in high-risk neuroblastoma (established via CCG-3891) | CCG-3891 | Event-free survival (EFS) | Improved EFS after myeloablative therapy; became standard maintenance and the backbone onto which anti-GD2 immunotherapy was added |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in neuroblastoma development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| hu14.18-IL2 immunocytokine — COG ANBL0322 (phase II, relapsed/refractory) | Limited activity in measurable soft-tissue disease; did not advance to broad approval | Insufficient responses in bulky disease and toxicity limited development despite biologic rationale |
| various tyrosine kinase / ALK inhibitors (early monotherapy) — Early-phase pediatric studies (e.g., crizotinib in ALK-aberrant neuroblastoma) | Modest single-agent activity; frequent resistance | ALK mutations differ from ALK fusions and often confer partial resistance to first-generation inhibitors, requiring newer agents and combinations |
Choosing the right endpoint
Primary endpoints that matter in neuroblastoma trials
- Event-free survival (EFS) — Primary endpoint in high-risk neuroblastoma trials such as ANBL0032, capturing relapse, progression, or death
- Overall survival (OS) — Definitive endpoint given the poor prognosis of high-risk disease
- Objective response rate (ORR) — Basis for accelerated approvals in relapsed/refractory disease, e.g., naxitamab
- Minimal residual disease / metaiodobenzylguanidine (MIBG) response — Imaging (Curie score) and molecular measures used to assess depth of response and bone marrow involvement
- MYCN amplification status — Key prognostic biomarker defining high-risk disease and stratifying therapy intensity
How iNGENū runs neuroblastoma trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Neuroblastoma clinical trials — FAQs
What makes neuroblastoma high-risk?
How does anti-GD2 immunotherapy work?
Why is relapsed neuroblastoma so hard to treat?
Ready to discuss your neuroblastoma trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal